Building a world where
tomorrow is another day!

Home
サブ-ナビゲーション
  • Company
  • Science/Pipleline
  • News
  • Investor Relations
  • Career
  • Contact
  • Privacy Policy
  • Term of use
  • Sitemap

Home

News

  • Jun 15, 2026 Announcement of Dose-Escalation Cohort Data for Rogocekib Presented at the EHA Congress 2026 pdf (338KB)
  • May 19, 2026 Chordia Therapeutics Publishes First-in-Human Phase 1 Results of CLK Inhibitor Rogocekib for Solid Tumors in Clinical Cancer Research pdf (350KB)
  • May 13, 2026 Acceptance and Publication of Abstract on Dose-Escalation Cohort Data of rogocekib (CTX-712) at EHA 2026 pdf (270KB)
  • Apr 24, 2026 (delayed)Notice of Release of Transcript of Interim Financial Results Briefing for the Fiscal Year Ending August 31, 2026 pdf (313KB)

View All

Science

Science

Science

Development Pipeline

Development Pipeline

CLK Inhibitor CTX-712

CLK Inhibitor CTX-712

MALT1 Inhibitor CTX-177

MALT1 Inhibitor CTX-177

CDK12 Inhibitor CTX-439

CDK12 Inhibitor CTX-439

GCN2 Inhibitor CRD-1968099

GCN2 Inhibitor CRD-1968099

View All

Investor Relations
Investor Relations

Company

Corporate Name Chordia Therapeutics Inc.
Foundation November 1, 2017
Head Office 26-1, Muraoka-Higashi 2-chome,Fujisawa, Kanagawa 251-0012 Japan MAP
Tokyo Office 3-11-5,Nihonbashi-honcho,Chuo-ku,Tokyo 103-0023 Japan
Representative Hiroshi Miyake, Ph.D. CEO

Mission

Message

Leadership
Team

Career

Career

Career

Contact

Contact

ページの先頭へ
ページの先頭へ
  • footer-content
  • menu
  • gnavi-box